Q4 2020 Bergenbio ASA Earnings Call Transcript
Good morning, and welcome to BerGenBio's 2020 Quarter 4 and Year-End Report, Highlights and Financial Summary. My name is Richard Godfrey, and I'm the CEO of BerGenBio. I'm joined this morning by Rune Skeie, our CFO; and Hani Gabra, our Chief Medical Officer.
Our presentation and our quarterly report can be found on our website. Next slide, please. I should draw your attention to our forward-looking statements and safe harbor comments on Slide 2.
Next slide, please. We have quite a broad agenda today. To introduce you to our recent highlights, a summary of our biotechnology around AXL tyrosine kinase and our lead candidate bemcentinib, an update on our clinical trials, a comment on tilvestamab, our anti-AXL monoclonal antibody, a report on our financial status and an outlook for 2021.
Next slide, please. As a way of a reminder and introduction to BerGenBio, we are world leaders in understanding the role and function of AXL tyrosine kinase, specifically as it mediates aggressive diseases, including immune-evasive therapy resistant and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |